Develops oral medicines for immune-inflammatory diseases.
Jun 2026Revenue $105M/yrExpenses $455M/yr
No trendCash runway ≈ 2.9 years from Jun 2026
Figures by year
When will Kymera Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $105M and expenses $455M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $39.2M | $389M | −$349M |
| Dec 2024 | $47.1M | $309M | −$262M |
| Dec 2023 | $78.6M | $244M | −$166M |
| Dec 2022 | $46.8M | $208M | −$161M |
| Dec 2021 | $72.8M | $173M | −$101M |
| Dec 2020 | $34.0M | $80.3M | −$46.3M |
| Dec 2019 | $2.93M | $45.1M | −$42.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.